Sana Biotechnology (SANA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.13
- Estimate
- -$0.12
- Surprise
- -7.9%
- Score today
- 4.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Sana Biotechnology (SANA) reported a wider loss than forecast — adjusted EPS of -$0.13 against the -$0.12 estimate (a 7.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SANA Sell at 4.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -7.9% surprise compares with a -0.9% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $8.43 vs price $2.75 — ratio 3.1×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (9 sells, 4.09% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.75
- Price target
- $3.45
- Stop
- $2.66
- Upside to target
- +25.5%
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
SANA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $862.2M
- P/E (fwd)
- -5.2
- 52-week range
- $2.61–$6.55
- Off 52-week high
- 58.0%
- RSI (14)
- 42
- Volume vs avg
- 0.88×
- Score today
- 4.2/10